Oneness Biotech Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 6 to 13, 2027 · next Feb 6
- 1 fee due May 28, 2027The maintenance fee for Methods for preparation of Plectranthus amboinicus extracts (US 11,826,395) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Antibodies to interleukin-6 (US 9,234,035) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,517,604 | Method for preparing Plectranthus amboinicus fraction having anti-arthritis activity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,758,580 | Uses of antibodies to interleukin-6 in cancer treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 10,370,443 | Method of treating autoimmune disease by administering antibodies to interleukin-6 In force · From the USPTO record | In force | From the USPTO record | |
| US 9,234,035 | Antibodies to interleukin-6 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,376,488 | Use of flavonoids in manufacturing compositions for wound healing In force · From the USPTO record | In force | From the USPTO record | |
| US 9,540,673 | Methods for producing recombinant glycoproteins with modified glycosylation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,745,729 | Methods for producing recombinant glycoproteins with modified glycosylation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,884,801 | Compounds from antrodia camphorata, method for preparing the same and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,758,584 | Topical formulation for promoting wound healing In force · From the USPTO record | In force | From the USPTO record | |
| US 11,439,682 | Treating IgE-mediated allergic diseases In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 5 no status recorded